

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032929 A2

(51) International Patent Classification⁷: **A61K 31/473**,
C07D 219/12, 401/12, 417/12

(21) International Application Number:
PCT/GB2003/004314

(22) International Filing Date: 7 October 2003 (07.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0223494.6 9 October 2002 (09.10.2002) GB

(71) Applicant (for all designated States except US): **NEUROPHARMA, S.A.** [ES/ES]; Jose Abascal 2, E-28003 Madrid (ES).

(71) Applicant (for SD only): **RUFFLES, Graham, Keith** [GB/GB]; Wellington House, East Road, Cambridge CB1 1BH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MARTINEZ GIL, Ana** [ES/ES]; Calle Santa Teresa 12, 2 Izquierda, E-28004 Madrid (ES). **DORRONSORO DIAZ, Isabel** [ES/ES]; C/Valliciego, 3 Portal 3 5° A, E-28005 Madrid (ES). **RUBIO ARRIETA, Laura** [ES/ES]; C/Esalona 57 7°3, E-28024 Madrid (ES). **ALONSO GORDILLO, Diana** [ES/ES]; C/Ramón y Cajal, 2 Portal 8 3°C, E- Madrid (ES). **FUERTE HUERTA, Ana** [ES/ES]; C/Alenza 9, 5° derecha, E-28003 Madrid (ES). **MORALES-ALCELAY, Susana** [ES/ES]; Avda. Infante Don Luis, n°14, P3, 1°A,

Boadilla del Monte, E-28660 Madrid (ES). **DEL MONTE MILLÁN, Maria** [ES/ES]; C/Ramón Gómez de la Serna, n°51, 2A, E-28035 Madrid (ES). **GARCIA PALOMERO, Esther** [ES/ES]; C/Santa Teresa, n°7, 3 Izda, Leganés, E-28911 Madrid (ES). **USAN EGEA, Paola** [ES/ES]; C/Doctor Varela 31, 3°A Alpedrete, E-28430 Madrid (ES). **DE AUSTRIA, Celia** [ES/ES]; Avda. Moratalaz 29, Bj-C, E-28030 Madrid (ES). **MEDINA PADILLA, Miguel** [ES/ES]; C/Antonio López Aguado, 9; 9° G, E-28029 Madrid (ES).


(74) Agent: **RUFFLES, Graham, Keith**; Marks & Clerk, 66/68 Hills Road, Cambridge, Cambridgeshire CB2 1LA (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE



(57) Abstract: A family of compounds of formula (I) wherein: X is one of the following radicals: which behaves as dual site acetylcholinesterase inhibitors and which are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.



Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

FIELD OF THE INVENTION

The invention relates to a novel family of compounds which behaves as dual site acetylcholinesterase inhibitors, as well as to the synthesis and biological evaluation of the compounds of said family. These compounds are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease. Thus, the invention also relates to pharmaceutical compositions containing said compounds.

BACKGROUND OF THE INVENTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder which is one of the most common causes of mental deterioration in elderly people, accounting for about 50-60 % of the overall cases of dementia among persons over 65 years of age. Demographic data indicate that the percentage of elderly in the population is increasing.


Brain regions that are associated with higher mental functions, particularly the neocortex and hippocampus, are those most affected by the characteristic pathology of AD. This includes the extracellular

deposits of β -amyloid (derived from amyloid precursor protein, APP) in senile plaques], intracellular formation of neurofibrillary tangles (containing an abnormally phosphorylated form of a microtubule associated protein, tau), and the loss of neuronal synapses and pyramidal neurons.


The past two decades have witnessed a considerable research effort directed towards discovering the cause of AD with the ultimate hope of developing safe and effective pharmacological treatments. Nowadays, research in the knowledge of the pathogenic cascade that characterizes AD has provided a robust framework for new therapeutic intervention targets.

Nevertheless, current treatment approaches in this disease continue being primarily symptomatic, with the major therapeutic strategy based on the cholinergic hypothesis and specifically on acetylcholinesterase (AChE) inhibition. The successful development of these compounds was based on a well-accepted theory that the decline in cognitive and mental functions associated with AD is related to the loss of cortical cholinergic neurotransmission. This link between cholinergic dysfunction in the basal-cortical system and cognitive deficits has focused scientific efforts on developing tools to elucidate the neurobiological role of the cholinergic system in cognition and to elucidate therapeutic interventions in the disorder. As result, over last decade, the cholinergic hypothesis of AD has launched on the market various cholinergic drugs primarily AChE inhibitors as tacrine, donepezil or rivastigmine, and more recently galanthamine, indicated modest improvement in the cognitive function of Alzheimer's patients.


3




Tacrine



Donepezil



Rivastigmine



Galanthamine

The three dimensional structure of AChE, as determined by x-ray crystallography, revealed that its active site can apparently be reached only through a deep and narrow catalytic gorge. Inhibitors of AChE act on two target sites on the enzyme, the active site and the peripheral site. Inhibitors directed to the active site prevent the binding of a substrate molecule, or its hydrolysis, either by occupying the site with a high affinity molecule (tacrine) or by reacting irreversibly with the catalytic serine (organophosphates and carbamates). The peripheral site consists of a less well-defined area, located at the entrance of the catalytic gorge. Inhibitors that bind to that site include small molecules, such as propidium and peptide toxins as fasciculins. Bis-quaternary inhibitors as decamethonium and others, simultaneously bind to the active and peripheral sites, thus occupying the entire catalytic gorge.

Parallel to the development of antidementia drugs, research efforts have been focused, among others, on the therapeutic potential of AChE inhibitors to slow the disorder progression. This fact was based on a range of evidence, which showed that AChE has secondary non-cholinergic functions.

New evidence shows that AChE may have a direct role in neuronal differentiation. Transient expression of AChE in the brain during embryogenesis suggests that AChE may function in the regulation of neurite outgrowth and in the development of axon tracts. Additionally, the role of AChE in cell adhesion have been studied. The results indicate that AChE promotes neurite outgrowth in neuroblastoma cell line through a cell adhesive role. Moreover, recent studies have shown that the peripheral anionic site of the AChE is involved in the neurotrophic activity of the enzyme and conclude that the adhesion function of AChE is located at the peripheral anionic site. This finding has implications, not only for our understanding of neural development and its disorders, but also for the treatment of neuroblastoma, the leukemias, and especially for Alzheimer's disease.

As it has been previously mentioned, senile plaques are one of pathological hallmarks in AD in which their main component is β A peptide. This is found as an aggregated poorly soluble form. In contrast soluble β A is identified normally circulating in human body fluids. Structural studies of β A showed that synthetic peptides containing the sequences 1-40 and 1-42 of β A can adopt two major conformational states in solution: an amyloidogenic conformer (β A ac) with a high content of β -sheet and partly resistant to proteases and a non-amyloidogenic conformer (β A nac) with a random coil conformation or α -helix and protease-sensitive. AChE colocalizes with β A peptide deposits present in the brain of Alzheimer's patients. It is postulated that AChE binds to a β A nac form acting as a "pathological chaperone" and inducing a conformational transition from β A nac into β A ac in vitro and therefore to amyloid fibrils. AChE directly promotes the assembly of β A peptide into amyloid fibrils forming stable β A-AChE complexes. These complexes are able to change the biochemical and pharmacological properties of the enzyme and cause an increase in the

neurotoxicity of the β A fibrils. Moreover, the interaction between these two molecules to form the complex was confirmed by crosslinking experiments. Different studies concerned to the establishment of the binding site of AChE on A β have suggested that hydrophobic interactions may play a role in the stabilization of the β A-AChE complex probably due to specific binding to peripheral sites.

Considering the non-cholinergic aspects of the cholinergic enzyme AChE, their relationship to Alzheimer's hallmarks and the role of the peripheral site of AChE in all these functions, an attractive target for the design of new antidementia drugs emerged. Peripheral or dual site inhibitors of AChE may simultaneously alleviate the cognitive deficit in Alzheimer's patients and what it is more important, avoid the assembly of beta-amyloid which represents a new way to delay the neurodegenerative process.

As revealed by the crystallographic structure of AChE and their inhibitors complexes, the AChE active site contains a catalytic triad (Ser 200, His 440, Glu 327) located at the bottom of a deep and narrow gorge, lined with aromatic residues and a subsite, including Trp 84, located near the bottom of the cavity. Trp 84 has been identified as the binding site of the quaternary group of acetylcholine, decamethonium and edrophonium. In addition, Trp 279 at the peripheral site, located at the opening of the gorge, is involved in the binding of the second quaternary group of decamethonium being responsible for the adhesion function of the enzyme.

These residues (Trp 84 and 279) have been the basis of the design of a new generation of AChE inhibitors. Thus, ligands able to interact simultaneously with active and peripheral sites could implicate several advantages over the known inhibitors. On one hand, they should


improve greatly the inhibitory potency and on the other hand they should be involved in neurotrophic activity. Reference is made to the accompanying Figure.

SUMMARY OF THE DRAWING

The Figure is a model of the catalytic gorge of AChE

Derivatives that in view of their chemical structure might be classified as dual AchE inhibitors have been reviewed, see Castro, A.; Martinez, A. *Mini Rev. Med. Chem.*, 2001, 1, 267-272. One of the compounds therein reported, a bis-galanthamine inhibitor, is recently described by molecular modelling techniques as a bis-functional ligand for the AchE, see Luttmann, E.; Linnemann, E.; Fels, G. *J. Mol. Model.*, 2002, 8, 208-216.

The following compounds might also be classified as dual AchE inhibitors:



In particular, US Patent 6,194,403 describes bis-halo-tacrinyllalkanes for use in the treatment of Alzheimer's disease.

SUMMARY OF THE INVENTION


We have applied this new concept for the design of dual AchE inhibitors, in order to have compounds that show potent AchE inhibition activities together with modifications in the β -amyloid aggregation properties.

In particular, after extensive research, we have developed a new family of compounds which show potent AchE inhibition activities together with modifications in the β -amyloid aggregation properties.

The invention discloses a novel family of compounds which behaves as dual site acetylcholinesterase inhibitors, as well as to the synthesis and biological evaluation of the compounds of said family. These compounds are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinker disease. The invention also relates to pharmaceutical compositions containing said compounds.

DETAILED DESCRIPTION OF THE INVENTION


The invention is directed to the compounds represented by the general formula I



Formula I

wherein:

X is one of the following radicals:



L is independently selected from $-\text{C}(\text{R})(\text{R}')-$, $-\text{CO}-$, $-\text{O}-$ or $-\text{NR}'-$

n is zero, one, two, three, four, five, six, seven, eight, nine or ten

R and R' are independently selected from hydrogen, alkyl, aryl, heteroaryl, halo, haloalkyl, alkoxy, hydroxyl, nitro and alkylthio

D is independently selected from $-\text{C}(\text{R}_9)-$, $=\text{C}-$, or $-\text{N}-$

A₁, A₂, A₃, A₄, A₅, A₇, A₈, B₁, B₂, B₃, B₄, B₅, B₆, B₇, B₈, G and E are independently selected from $-\text{CO}-$, $-\text{C}(\text{R}_{10})(\text{R}_{11})-$, $=\text{C}(\text{R}_{10})-$, $-\text{N}(\text{R}_{12})-$, $=\text{N}-$, $-\text{O}-$, $-\text{S}(\text{O})_t-$

R₁, R₂, R₃, R₄, R₉, R₁₀ and R₁₁ are independently selected from hydrogen, alkyl, alkoxy, hydroxyl, alkylthio, cycloalkyl, haloalkyl, halo, aryl, $-(\text{Z})_n-$, aryl, heteroaryl, $-\text{O}(\text{R}_7)$, $-\text{C}(\text{O})\text{R}_7$, $-\text{C}(\text{O})\text{OR}_7$, $-\text{S}(\text{O})_t$, cyano, nitro and mercapto, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

R₅, R₆, and R₁₂ are independently selected from hydrogen, alkyl, alkoxy, hydroxyl, cycloalkyl, haloalkyl, aryl, heteroaryl, aryl


substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

Z is independently selected from $-C(R_7)(R_8)-$, $-C(O)-$, $-O-$, $-C(=NR_7)-$, $-S(O)_t$, $N(R_7)-$

R_7 and R_8 are independently selected from hydrogen, alkyl, alkoxy, alkylthio, cycloalkyl, haloalkyl, halo, aryl, heteroaryl, cyano, nitro, mercapto, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio


t is zero, one or two.

In general, we have the proviso that when X is:



- a) in no case each of the atoms in the groups A_1-A_4 , A_5-A_8 , B_1-B_4 , and B_5-B_8 are at the same time $=C(R_{10})-$, and
- b) in no case each of the atoms in one of the two groups A_1-A_4 and A_5-A_8 , and each of the atoms in one of the two groups B_1-B_4 and B_5-B_8 are at the same time $=C(R_{10})-$.

In a related aspect, the invention is directed to the compounds within the formula (I) and represented by the general formula Ia and IIa:



Where:

X is $-C(R^{1a})(R^{2a})-$, $-CO-$, $-O-$ or $-NR^{1a}-$;

n is zero, one, two, three, four, five, six, seven, eight, nine or ten;

R^{1a} and R^{2a} are independently selected from hydrogen, alkyl, aryl, halo, haloalkyl;

R^{3a} , R^{4a} and R^{5a} are independently selected from hydrogen, alkyl, cycloalkyl, haloalkyl, halo, aryl, $-(Z)_n$ -aryl, heteroaryl, $-OR^{3a}$, $-C(O)R^{3a}$, $-C(O)OR^{3a}$, $-S(O)_t$;

t is zero, one or two;

Z is independently selected from $C(R^{3a})(R^{4a})-$, $-C(O)-$, $-O-$, $-C(=NR^{3a})-$, $-S(O)_t-$, $N(R^{3a})-$.

Definitions

Unless otherwise specified, the following terms have the following meaning::

- “alkyl” refers to a straight-line or branched hydrocarbon chain comprising only atoms of carbon and hydrogen and containing no unsaturated bonds, having from one to eight carbon atoms and bound to the remainder of the molecule by a single bond, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. The alkyl radicals may optionally be substituted by one or more substituents chosen independently from the group comprising halogens, hydroxyl, alcoxides, carboxy, cyano, carbonyl, acyl, alkoxy carbonyl, amino, nitro, mercapto and alkylthio. Preferably, alkyl is C₁-C₆ alkyl.
- “alkoxy” refers to a radical of formula -OR_a, where R_a is an alkyl radical as described above, e.g. methoxy, ethoxy, propoxy, etc.
- “alkoxycarbonyl” refers to a radical of formula -C(O)OR_a, where R_a is an alkyl radical as described above, e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, etc.
- alkylthio” refers to a radical of formula -SR_a, where R_a is an alkyl radical as described above, e.g. methylthio, ethylthio, propylthio, etc.
- “amino” refers to a radical of formula -NH₂
- “aryl” refers to a phenyl or naphthyl radical. The aryl radical may optionally be substituted by one or more substituents selected from among the group comprising hydroxy, mercapto, halogens, alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl and alkoxy carbonyl as they are defined here.
- “acyl” refers to a radical of formula -C(O)-R_a and -C(O)-R_b, where R_a is an alkyl radical as described above and R_b is an aryl

radical as described above, e.g. acetyl, propionyl, benzoyl, and similar.

“carboxy” refers to a radical of formula -C(O)OH

“cyano” refers to a radical of formula -CN

“cycloalkyl” refers to stable cycles of 3 to 10 monocyclic or bicyclic members that are saturated or partially saturated and consist exclusively of carbon and hydrogen atoms. This term also includes cycloalkylo radicals, which may optionally be substituted by one or more substituents chosen independently from the group comprising alkyl, halogen, hydroxy, amino, cyano, nitro, alkoxy, carboxy and alkoxycarbonyl

“halogens” refers to bromine, chlorine, iodine or fluorine

“haloalkyl” refers to an alkyl radical, as defined above, which is substituted by one or more halogens, also as defined above, e.g. trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and similar.

“heterocycle” refers to a heterocyclic radical. The heterocycle refers to a stable cycle of 3 to 15 members comprising carbon atoms and one to five heteroatoms chosen from the group comprising nitrogen, oxygen and sulphur. For the purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic system that may include fused rings, and the nitrogen, carbon or sulphur atoms may optionally be oxidised, the nitrogen atom may optionally be quaternised, and the heterocycle may be partly or totally saturated or aromatic. Examples of these heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran. The heterocycle may


optionally be substituted by R_3 and R_4 as defined in the summary of the invention.

“mercapto” refers to a radical of formula $-SH$

“nitro” refers to a radical of formula $-NO_2$.

In the chain $-(L)_n-(L)_n-(L)_n-(L)_n-(L)_n-$, the or each group $-(L)_n-$ is preferably $-(CH_2)_n-$ (where n is not zero), $-CO-$, $-NH-$ or $-NCH_3-$. Preferably there are at least one or two groups $-(L)_n-$ where n is not zero. Suitably the chain is of the formula $-(CH_2)_n-$, $-(CH_2)_n-NR_a-$, $-(CH_2)_n-$, $-(CH_2)_n-NR_a-CO-$, $-(CH_2)_n-NR_a-CO-(CH_2)_n-$ or $-(CH_2)_n-NR_a-(CH_2)_n-NR_a-CO-$, where the or each n is not zero, and the or each R_a is $-NH-$ or $-NCH_3-$, usually preferably $-NH-$. The total for the sum of the n integers is preferably in the range 2 to 15.


In the formula:



each A group (that is, A_1 to A_8) is preferably $=CH-$ or $-CH_2-$, though one or both of A_2 and A_7 can be halo, especially chloro, when the remaining A groups are $=CH-$.

The preferred compounds of the present invention are those in which X is represented by the following formula:

15



Preferably D is $-\text{CH}-$, $=\text{C}-$ or $-\text{N}-$. Preferably E is $-\text{CO}-$, $-\text{CH}_2-$, $=\text{CH}-$, $=\text{N}-$, $-\text{O}-$ or $-\text{S}-$. Preferably G is $-\text{CO}-$, $-\text{CH}_2-$, $=\text{CH}-$, or $=\text{N}-$. Preferably R_1 to R_4 are hydrogen.

Especially preferred within these compounds are those in which X is: phthalimidyl (1,3-dioxo-1,3-dihydro-isoindol-2-yl), indol-2-yl, indanon-2-yl, benzimidazol-2-yl, indandion-2-yl, indazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl or benzotriazol-2-yl.

More preferred compounds are those in which X is phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl) and the cyclic part of formula I represents 9-acridinyl, 1,2,3,4-tetrahydro-acridin-9-yl or 6-chloro,1,2,3,4-tetrahydro-acridin-9-yl. Some preferred compounds are:


- 2-[6-(acridin-9-ylamino)-hexyl]-isoindole-1,3-dione (6),
- 2-[7-(acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (7),
- 2-[8-(acridin-9-ylamino)-octyl]-isoindole-1,3-dione (8),
- 2-[9-(acridin-9-ylamino)-nonyl]-isoindole-1,3-dione (9),
- N-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (10),
- N-(3-[[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino}-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (11),
- N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (12),
- 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione (3),

- 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (4), and
- 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione (5)

More preferred compounds are those in which X is 1-indanon-2-yl and the cyclic part of formula I represents 1,2,3,4-tetrahydro-acridin-9-yl; within these compounds are included, among others, the following compounds:

- 5,6-Dimethoxy-2-{[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl}-indan-1-one (1), and
- 5,6-Dimethoxy-2-{[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl}-indan-1-one (2)

From those compounds in which X is represented by the following formula:




each B group (that is, B₁ to B₈) is preferably =CH- or -CH₂-, though one or both of B₂ and B₇ can be halo, especially chloro, when the remaining B groups are =CH-. The preferred compounds are those in which X is 9-acridinyl, 6-chloro-1,2,3,4-tetrahydro-acridin-9-yl and 1,2,3,4-tetrahydro-acridin-9-yl. More preferred within these compounds are those in which the cyclic part of formula I represents: 9-acridinyl, 6-chloro-1,2,3,4-tetrahydro-acridin-9-yl or 1,2,3,4-tetrahydro-acridin-9-

yl; within these compounds are included, among others, the following compounds:

- N-[2-(6-Chloro-1,2,3,4,4a,9a-hexahydro-acridin-9-ylamino)-ethyl]-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-*N*-methyl-ethane-1,2-diamine (19),
- *N*-Acridin-9-yl-*N'*-(1,2,3,4-tetrahydro-acridin-9-yl)-nonane-1,9-diamine (20)
- *N*-Acridin-9-yl-*N'*-[2-(1,2,3,4,4a,9a-hexahydro-acridin-9-ylamino)-ethyl]-*N'*-methyl-ethane-1,2-diamine (21) ,
- *N*-[2-(Acridin-9-ylamino)-ethyl]-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-*N*-methyl-ethane-1,2-diamine (22),
- *N*-Acridin-9-yl-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-heptane-1,7-diamine (23), and
- *N*-Acridin-9-yl-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-octane-1,8-diamine (24).

From those compounds in which X is represented by the following formula:




the groups R_5 and R_6 are suitably alkyl or substituted alkyl, notably alkoxy carbonyl alkyl. The preferred compounds are those in which the cyclic part of formula I represents: 9-acridinyl, 6-chloro,1,2,3,4-tetrahydro-acridin-9-yl or 1,2,3,4-tetrahydro-acridin-9-yl; within these compounds are included, among others, the following compounds:

- 2-Ethyl-4-isopropyl-5-[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl-iminio]-[1,2,4]thiadiazolidin-3-one (13),
- 2-Ethyl-4-isopropyl-5-[9-(1,2,3,4-tetrahydro-acridin-9-ylamino)-nonyl-iminio]-[1,2,4]thiadiazolidin-3-one (14),

- 4-isopropyl-3-oxo-5-[9-(1,2,3,4-tetrahydro-acridin-9-ylamino)-nonyl-iminio]-[1,2,4]thiadiazolidine-2-carboxylic acid ethyl ester (15),
- 4-Ethyl-2-propyl-5-[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl-imino]-[1,2,4]thiadiazolidin-3-one (16),
- 4-Ethyl-2-isopropyl-5-[8-(1,2,3,4-tetrahydro-acridin-9-ylamino)-octylimino]-[1,2,4]thiadiazolidin-3-one (17), and
- 4-Ethyl-2-isopropyl-5-[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl-imino]-[1,2,4]thiadiazolidin-3-one (18).


Another object of the invention is the synthesis of the compounds of the invention.

The synthesis of the compounds follow a convergent pathway strategy that could be summarized in schemes 1a, 1b, 2 and 3.




SCHEME 1a


19



SCHEME 1b



SCHEME 2




SCHEME 3

9-Alkylaminotetrahydroacridines have been synthesized following the procedure previously reported in bibliography. Carrier, P.R.; Chow. E.S.-H; Han, Y.; Liu, J.; El Yazal, J.; Pang Y.-P. *J. Med. Chem.*, 1999, 42, 4225-4231.

Specific examples are:

Example 1: 5,6-Dimethoxy-2-[[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl]-indan-1-one.




To a stirred solution of 9-(7-aminoheptylamino)-1,2,3,4-tetrahydroacridine (134 mg, 0.43 mmol) in a mixture of ethanol: water 3:1 (3.5 ml) at room temperature, paraformaldehyde (26 mg, 0.86 mmol) and 5,6-dimethoxyindan-1-one (83 mg, 0.43 mmol) were added. The pH was adjusted to 3 with 35% hydrochloric acid and the mixture were refluxed for 24 hours. At the end of this period, the reaction mixture was cooled (25°C), the solvent was removal under vacuum pressure and the residue was treated with K₂CO₃ saturated solution (3.5 ml) and methylene chloride (5 ml). The organic layer was washed with water (5 ml) and dried (anhydrous Na₂SO₄). The solvent was removed under vacuum and the residue was purified by preparative centrifugal thin layer chromatography. Elution with 5: 1 ethyl acetate: methanol containing 1% of aqueous ammonia afforded the title compound as yellow syrup (15 mg, 6.8 %).

¹H-NMR (CDCl₃, 300MHz, δ): 7.93 (dd, 2H, J=8.2 Hz), 7.53 (ddd, , 1H, J=8.2, 1.3 Hz), 7.32 (ddd, , 1H, J=8.2, 1.3 Hz), 7.13 (s, 1H), 6.85 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H), 3.48 (t, 2H, J=7.1 Hz), 3.28-3.19 (m, 1H), 3.10-3.05 (m, 2H), 2.89-2.56 (m, 9H), 1.91-1.88 (m, 4H), 1.63 (quint, 2H, J=7.5 Hz), 1.50-1.37 (m, 2H), 1.34-1.32 (m, 6H).

¹³C-NMR (CDCl₃, 300MHz, δ): 203.0, 155.9, 151.3, 149.7, 149.6, 129.6, 128.8, 128.4, 123.9, 123.2, 107.6, 104.4, 56.5, 56.4, 51.5, 50.1, 49.7, 33.9, 31.9, 31.6, 30.0, 29.5, 27.4, 27.1, 27.0, 24.9, 23.2, 22.9.

ESI-MS: m/z [M+H⁺]⁺ 516.

Example 2: 5,6-Dimethoxy-2-[[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl]-indan-1-one.




According to the general procedure in Example 1, 9-(6-aminohexylamino)-1,2,3,4-tetrahydroacridine (96 mg, 0.32 mmol), paraformaldehyde (19 mg, 0.64 mmol), 5,6-dimethoxyindan-1-one (62 mg, 0.32 mmol) and 35% hydrochloric acid (pH=3) were refluxed for 24 hours. Purification by two preparative centrifugal thin layer chromatographies eluting with 10: 1 ethyl acetate: methanol containing 2% of aqueous ammonia afforded the title compound as yellow syrup (8 mg, 5 %).

$^1\text{H-NMR}$ (CDCl_3 , 300MHz, δ): 7.97 (dd, 2H, $J=8.1$ Hz), 7.56 (ddd, , 1H, $J=8.1$, 1.2 Hz), 7.34 (ddd, , 1H, $J=8.2$, 1.2 Hz), 7.13 (s, 1H), 6.85 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H), 3.55 (t, 2H, $J=7.0$ Hz), 3.30-3.19 (m, 1H), 3.10-3.07 (m, 2H), 2.90-2.60 (m, 7H), 1.89-1.68 (m, 4H), 1.40-1.35 (m, 2H), 1.28-1.11 (m, 6H).

$^{13}\text{C-NMR}$ (CDCl_3 , 300MHz, δ): 207.1, 155.7, 151.2, 149.4, 149.3, 129.3, 128.7, 128.3, 123.8, 123.0, 107.4, 104.2, 56.3, 56.1, 51.3, 49.7, 49.4, 47.3, 31.6, 31.3, 29.7, 27.0, 24.6, 22.9, 22.5.

ESI-MS: m/z $[\text{M}+\text{H}^+]^+$ 502.

Example 3. 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione



To a stirred solution of (1,2,3,4-Tetrahydro-acridin-9-yl)-hexane-1,6-diamine oxalate (339 mg, 0.87 mmol) in a mixture of ethanol: water 3:1 (3.5 ml) at room temperature, paraformaldehyde (26,4 mg, 0.88 mmol) and Indan-1,3-dione (129 mg, 0.88 mmol) were added. The pH was adjusted to 3 with 35% hydrochloric acid and the mixture were refluxed for 24 hours. At the end of this period, the reaction mixture was cooled (25°C), the solvent was removal under vacuum pressure and the residue was treated with K₂CO₃ saturated solution (3.5 ml) and methylene chloride (5 ml). The organic layer was washed with water (5 ml) and dried (anhydrous Na₂SO₄). The solvent was removed under vacuum and the residue was purified by preparative centrifugal thin layer chromatography. Elution from 10:1 to 3:1 ethyl acetate: methanol containing 1% of aqueous ammonia afforded the title compound as yellow syrup (17 mg, 4.4 %).

¹H-NMR (CDCl₃, 400MHz, δ): 7.92 (m, 4H), 7.84 (dd, 2H, $J=6$, $J=2.8$, Hz), 7.54 (m, 1H), 7.32 (m, 1H), 3.70(t, 2H, $J=6.4$), 3.60 (m, 1H), 3.50 (t, 2H, $J=6.4$), 3.08 (m, 2H), 2.65 (m, 2H), 3.18-2.0(m, 4H), (1.80, 2H, m), (1.70, m, 2H), (1.45, m, 4H)

¹³C-NMR (CDCl₃, 300MHz, δ): 200.0, 159.0, 151.3, 147.1, 140.6, 136.8, 136.1, 130.5, 129.9, 123.6, 123.0, 120.8, 120.4, 53.1, 52.9, 49.3, 48.9, 31.4, 29.8, 26.7, 26.4, 24.7, 22.6, 22.0.


ESI-MS: m/z [M+H]⁺+442 .

General method for the synthesis of isoindol derivatives (Scheme 4, Examples 4-9)

To a solution of KOH in DMSO was added 9-Amino-1,2,3,4-tetrahydroacridine under N₂, and the mixture was stirred for 4 hours at room temperature. After this time the brominated alkyl isoindol


derivative was added and the resulting orange solution was stirred for 12 hours at room temperature, and then the solvent was eliminated washing with water and extracted with ethyl acetate. The combined organic extracts were washed with NaCl solution, and then were dried with Na₂SO₄ anhydrous. The solvent was evaporated under reduced pressure and the residue purified by silica gel column chromatography using as eluent mixtures of solvents in the proportions indicated for each case.

The brominated alkyl isoindol derivatives have been synthesized following the procedure previously reported in bibliography: Donahoe et al, J. Org.Chem, 22, 1957, 68.



SCHEME 4

Example 4. 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione



Reagents: 9-Amino-1,2,3,4-tetrahydroacridine (100 mg, 0.42 mmol), DMSO (5 ml), KOH (47 mg, 0.8 mmol), and 2-(7-Bromo-heptyl)-isoindole-1,3-dione (278 mg, 0.8 mmol).


Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (10:1:0.5%). Yellow syrup, yield: 17 mg (5%).

¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.41 (brs, 1H), 8.12 (d, 1H, $J=8.6$ Hz), 7.82 (dd, 2H, $J=5.0$ Hz, $J=2.7$ Hz), 7.68 (dd, 3H, $J=5.0$ Hz, $J=2.7$ Hz), 7.43 (t, 1H, $J=8.6$ Hz), 3.83 (brs, 2H), 3.65 (t, 2H, $J=7$ Hz), 3.25 (brs, 2H), 2.61 (t, 2H, $J=5.8$ Hz), 1.97-1.92 (m, 4H), 1.84-1.80 (m, 2H), 1.78-1.72 (m, 2H), 1.47-1.43 (m, 6H).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 168.5, 166.5, 154.0, 133.8, 132.5, 132.0, 131.2, 128.9, 125.3, 124.1, 123.3, 119.3, 54.6, 49.1, 38.5, 29.7, 29.2, 28.4, 28.2, 26.5, 25.2, 23.4, 22.9, 22.5, 22.1, 21.1, 14.4.

ESI-MS[M+H]⁺+443.

Example 5. 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione



Reagents: 9-Amino-1,2,3,4-tetrahydroacridine (100 mg, 0.42 mmol), DMSO (5 ml), KOH (47 mg, 0.8 mmol), and 2-(8-Bromo-octyl)-isoindole-1,3-dione (240 mg, 0.8 mmol).

Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (10:1: 0.5%). Yellow syrup, yield: 30 mg (15%).


¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.43 (brs, 1H), 8.12 (d, 1H, $J=8.6$ Hz), 7.82 (dd, 2H, $J=5.0$ Hz, $J=2.7$ Hz), 7.68 (dd, 3H, $J=5.0$ Hz, $J=2.7$ Hz), 7.43 (t, 1H, $J=8.6$ Hz), 3.83 (brs, 2H), 3.65 (t, 2H, $J=7$ Hz), 3.25 (brs,

2H), 2.61 (t, 2H, $J=5.8$ Hz), 1.97-1.92 (m, 4H), 1.84-1.80 (m, 2H), 1.78-1.72 (m, 2H), 1.47-1.43 (m, 8H).

^{13}C -NMR (CDCl_3 , 100MHz, δ ppm): 168.6, 166.2, 154.2, 134.1, 132.6, 132.3, 131.0, 129.0, 125.4, 124.0, 123.3, 119.3, 54.5, 49.0, 38.0, 29.8, 29.2, 28.9, 28.6, 26.7, 25.0, 23.6, 23.0, 22.8, 22.1, 21.0, 14.2.

ESI-MS $[\text{M}+\text{H}^+]^+$ 455.

Example 6. 2-[6-(Acridin-9-ylamino)-hexyl]-isoindole-1,3-dione



Reagents: 9-Amino-acridina (100 mg, 0.42 mmol), DMSO (5 ml), KOH (47 mg, 0.8 mmol), and 2-(6-Bromo-hexyl)-isoindole-1,3-dione (240 mg, 0.8 mmol).

Purification: silica gel column chromatography using DCM/ MeOH/ NH_3 (10:1:0.5%). Yellow syrup, yield: 30 mg (15%).


^1H -NMR (CDCl_3 , 400MHz, δ ppm): 8.08 (d, 2H, $J=8.6$ Hz), 8.02(d, 2H, $J=8.6$ Hz), 7.81 (dd, 2H, $J=5.4$ Hz, $J=3.1$ Hz), 7.68 (dd, 3H, $J=5.4$ Hz, $J=3.1$ Hz), 7.59 (t, 2H, $J=6.6$ Hz), 7.30 (t, 2H, $J=6.6$ Hz) 3.85 (t, 2H, $J=7$ Hz), 3.67 (t, 2H, $J=7$ Hz), 1.83 (q, 2H, $J=7$ Hz), 1.67 (q, 2H, $J=7$ Hz), 1.45-1.34 (m, 6H).

^{13}C -NMR (CDCl_3 , 100MHz, δ ppm): 168.2, 156.3, 133.8, 133.6, 131.9, 128.7, 128.5, 124.7, 123.0, 122.8, 119.3, 111.9, 48.4, 37.68, 29.81, 26.37, 22.81.

ESI-MS $[\text{M}+\text{H}^+]^+$ 424.

Example 7. 2-[7-(Acridin-9-ylamino)-heptyl]-isoindole-1,3-dione

27



Reagents: 9-Amino-acridine (60 mg, 0.24 mmol), DMSO (5 ml), KOH (27 mg, 0.48 mmol), and 2-(7-Bromo-heptyl)-isoindole-1,3-dione (80mg, 0.24 mmol).


Purification: silica gel column chromatography using DCM/ MeOH (10:1:0.1%NH₃). Yellow syrup, yield: 80 mg (74%).

¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.08 (d, 2H, J =8.6 Hz), 8.02 (d, 2H, J =8.6 Hz), 7.81 (dd, 2H, J =5.4 Hz, J =3.1 Hz), 7.68 (dd, 3H, J =5.4 Hz, J =3.1 Hz), 7.59 (t, 2H, J =6.6 Hz), 7.30 (t, 2H, J =6.6 Hz), 3.85 (t, 2H, J =7 Hz), 3.67 (t, 2H, J =7 Hz), 1.83 (q, 2H, J =7 Hz), 1.67 (q, 2H, J =7 Hz), 1.45-1.34 (m, 6H).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 168.3, 155.3, 133.8, 133.7, 132.7, 132.0, 124.5, 123.0, 122.9, 121.7, 113.2, 49.0, 37.7, 30.4, 28.6, 28.3, 26.6, 26.5.

ESI-MS[M+H⁺]⁺438.

Example 8. 2-[8-(Acridin-9-ylamino)-octyl]-isoindole-1,3-dione



Reagents: 9-Amino-acridina (60 mg, 0.24 mmol), DMSO (5 ml), KOH (27 mg, 0.48 mmol), and 2-(7-Bromo-heptyl)-isoindole-1,3-dione (68.64 mg, 0.24 mmol). Purification: silica gel column chromatography using DCM/ MeOH (10:1:0.1%NH₃). Yellow syrup, yield: 20 mg (18.5%).


¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.06 (d, 2H, J =8.6 Hz), 8.02 (d, 2H, J =8.6 Hz), 7.80 (dd, 2H, J =5.4 Hz, J =3.1 Hz), 7.68 (dd, 3H, J =5.4 Hz, J =3.1 Hz), 7.59 (t, 2H, J =6.6 Hz), 7.30 (t, 2H, J =6.6 Hz) 3.82 (t, 2H, J =7

Hz), 3.65 (t, 2H, $J=7$ Hz), 1.83 (q, 2H, $J=7$ Hz), 1.68 (q, 2H, $J=7$ Hz), 1.45-1.34 (m, 8H)

^{13}C -NMR (CDCl_3 , 100MHz, δ ppm): 168.3, 155.4, 134.1, 133.7, 132.7, 131.9, 124.6, 123.1, 122.8, 121.7, 113.1, 48.7, 37.6, 30.0, 28.5, 28.1, 26.4, 26.0, 23.2.

ESI-MS $[\text{M}+\text{H}^+]+451$.

Example 9. 2-[9-(Acridin-9-ylamino)-nonyl]-isoindole-1,3-dione



Reagents: 9-Amino-acridine (150 mg, 0.60 mmol), DMSO (10 ml), KOH (67.3 mg, 1.2 mmol), and 2-(9-Bromo-nonyl)-isoindole-1,3-dione (68.64 mg, 0.24 mmol). Purification: silica gel column chromatography using DCM/ MeOH (10:1:0.1% NH_3). Yellow syrup, yield: 20 mg (18.5%).

^1H -NMR (CDCl_3 , 400MHz, δ ppm): 8.06 (d, 2H, $J=8.6$ Hz), 8.02(d, 2H, $J=8.6$ Hz), 7.80 (dd, 2H, $J=5.4$ Hz, $J=3.1$ Hz), 7.68 (dd, 3H, $J=5.4$ Hz, $J=3.1$ Hz), 7.62 (t, 2H, $J=6.6$ Hz), 7.33 (t, 2H, $J=6.6$ Hz) 3.82 (t, 2H, $J=7$ Hz), 3.65 (t, 2H, $J=7$ Hz), 1.83 (q, 2H, $J=7$ Hz), 1.68 (q, 2H, $J=7$ Hz), 1.45-1.34 (m, 10H).

^{13}C -NMR (CDCl_3 , 100MHz, δ ppm): 168.3, 155.4, 134.2, 133.6, 132.7, 132.0, 124.2, 123.5, 122.5, 121.3, 113.0, 48.6, 37.6, 30.0, 27.5, 28.1, 26.2, 26.0, 23.2, 22.3.


ESI-MS $[\text{M}+\text{H}^+]+451$.

General method for the synthesis of *N*-phthaloglycine derivatives (Scheme 5, Examples 10-12)

To a solution of *N*-phthaloglycine in THF anhydrous was added 1,1'-carbonyldiimidazol under N_2 , and the mixture was stirred for 4


hours at room temperature. After this time the amine was added and the resulting amber solution was stirred for 20 hours, and then the solvent was evaporated under reduced pressure, water was added and the resulted mixture were extracted with dichlorometane. The combined organic extracts were washed with NaCl solution, and then were dried with Na₂SO₄ anhydrous. The solvent was evaporated under reduced pressure and the residue purified by silica gel column chromatography using as eluent mixtures of solvents in the proportions indicated for each case.

The derivatives of the present invention may be prepared as described below in scheme 5.



SCHEME 5

Example 10.- *N*-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide



Reagents: *N*-phthaloglycine (83 mg, 0.48 mmol), THF anhydrous (5 ml), 1,1'-carbonyldiimidazol (83 mg, 0.51 mmol), and 6-chloro-9-(7-aminoheptylamino)- 1,2,3,4-tetrahydroacridine (165 mg, 0.48 mmol).


Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (20:1:0.5%). Yellow syrup, yield: 80 mg (31%).

¹H-NMR (CDCl₃, 400MHz, δ ppm): 7.89 (d, 1H, *J*=8.9 Hz), 7.86 (d, 1H, *J*=2.3 Hz), 7.81 (dd, 2H, *J*=5.4 Hz, *J*=3.1 Hz), 7.68 (dd, 2H, *J*=5.4 Hz, *J*=3.1 Hz), 7.23 (dd, 1H, *J*=8.9 Hz, *J*=2.0 Hz), 6.22 (brs, 1H,), 4.32 (s, 2H), 4.18 (brs, 1H), 3.46-3.48 (m, 2H), 3.24 (c, 2H, *J*=6.6 Hz), 3.02 (brs, 2H), 2.65 (brs, 2H), 1.90 (m, 4H), 1.67-1.63 (m, 2H), 1.50-1.46 (m, 2H), 1.38-1.30(m, 4H).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 167.7, 166.3, 157.2, 152.0, 145.4, 135.1, 134.0, 131.6, 124.8, 124.6, 124.4, 123.2, 117.0, 114.3, 49.1, 40.5, 39.6, 32.1, 31.2, 29.1, 28.6, 26.5, 26.4, 24.3, 22.5, 22.0.

ESI-MS[M+H]⁺+533.

Example 11.- N-(3-{[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino}-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide



Reagents: *N*-phthaloglycine (160 mg, 0.78 mmol), THF anhydrous (10 ml), 1,1'-carbonyldiimidazol (126.5 mg, 0.78 mmol), and 6-chloro-9-(6-aminoheptylamino)- 1,2,3,4-tetrahydroacridine (260 mg, 0.78 mmol).


Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (20:1:0.5%). Yellow syrup, yield: 150 mg (37%).

¹H-NMR (CDCl₃, 400MHz, δ ppm): 7.81 (d, 1H, *J*=8.9 Hz), 7.73 (d, 1H, *J*=2.3 Hz), 7.68 (dd, 2H, *J*=5.4 Hz, *J*=3.1 Hz), 7.58 (dd, 2H, *J*=5.4 Hz, *J*=3.1 Hz), 7.13 (dd, 1H, *J*=8.9 Hz, *J*=2.0 Hz), 4.21 (s, 2H), 3.52-3.47 (m, 2H), 3.33 (brs, 2H), 3.28 (c, 2H, *J*=6.6 Hz), 3.24-3.21 (brs, 2H), 2.90 (brs, 2H), 2.34 (brs, 2H), 2.09 (s, 3H), 1.72 (m, 4H), 1.69 (q, 2H, *J*=6.6 Hz), 1.60 (q, 2H, *J*=6.6 Hz).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 167.5, 166.0, 157.6, 151.5, 146.0, 134.8, 134.7, 134.0, 131.7, 125.4, 124.8, 124.3, 123.3, 117.3, 114.6, 48.9, 40.8, 39.4, 32.8, 31.4, 29.3, 26.2, 25.6, 24.5, 22.7, 22.2.

ESI-MS[M+H⁺]⁺519.

Example 12.- N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide



Reagents: *N*-phthaloglycine (76 mg, 0.34 mmol), THF anhydrous (8 ml), 1,1'-carbonyldiimidazol (55.1 mg, 0.34 mmol), and 6-chloro-9-(6-aminohexylamino)-1,2,3,4-tetrahydroacridine (200 mg, 0.34 mmol).

Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (20:1:0.5%). Yellow syrup, yield: 60 mg (32%).

¹H-NMR (CDCl₃, 400MHz, δ ppm): 7.92 (d, 1H, *J*=8.9 Hz), 7.89 (d, 1H, *J*=2.3 Hz), 7.81 (dd, 2H, *J*=5.4 Hz, *J*=3.1 Hz), 7.70 (dd, 2H, *J*=5.4 Hz, *J*=3.1 Hz), 7.23 (dd, 1H, *J*=8.9 Hz, *J*=2.0 Hz), 6.04 (brs, 1H), 4.33 (s, 2H), 3.53-3.51 (m, 2H), 3.28 (c, 2H, *J*=6.6 Hz), 3.04 (brs, 2H), 2.60 (brs, 2H), 1.90 (m, 4H), 1.70-1.66 (m, 2H), 1.55-1.52 (m, 2H), 1.40-1.36 (m, 2H).


^{13}C -NMR (CDCl_3 , 100MHz, δ ppm): 167.5, 166.0, 157.3, 151.8, 145.4, 134.8, 133.9, 131.7, 124.9, 124.1, 123.1, 122.9, 117.0, 114.4, 56.2, 56.1, 48.8, 42.3, 40.8, 38.8, 32.3, 27.7, 26.1, 24.6, 22.7, 22.1.

ESI-MS[M+H] $^+$ +548.

General method for the synthesis of thiadiazolidinone derivatives (Scheme 2, Examples 13-18)

Chlorine was bubbled slowly through a solution of alkylisothiocyanate in dry hexane (15 ml) under nitrogen atmosphere at -15°C to -10°C . Chlorine was generated by addition of 35% HCl to KMnO_4 . The temperature of the reaction mixture was carefully controlled during the addition step. At this point the Alkyl-S-chloroisoithiocarbamoyl chloride was formed. Afterward, alkylisocyanate was added. The mixture was stirred at room temperature during 10 hours and the solvent was evaporated to dryness. The residue was resolved in anhydrous tetrahydrofuran (10 ml) after this point the amine and triethylamine were added. The reaction mixture was stirred for 24 hours at room temperature, the white solid was filtered off, The solvent was evaporated under reduced pressure and the residue purified by silica gel column chromatography using as eluent mixtures of solvents in the proportions indicated for each case.

Example 13: 2-Ethyl-4-isopropyl-5-[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl-iminio]-[1,2,4]thiadiazolidin-3-one.



Reagents: ethylisothiocyanate (569 μ l, 6.5 mmol), KMnO_4 (500mg, 3.16mmol), HCl (3.1ml, 3.4mmol), isopropylisocyanate (640 μ l, 6.5 mmol), triethylamine (94 μ l, 0.68 mmol) and 9-(7-aminoheptylamino)-1,2,3,4-tetrahydroacridine (105 mg, 0.34 mmol).


Purification: silica gel column chromatography using AcOEt/MeOH (4:1). yellow syrup (24 mg, 15%).

$^1\text{H-NMR}$ (CDCl_3 , 300MHz, δ): 8.36 (d, 1H, $J=8.4$ Hz), 8.09 (d, 1H, $J=8.4$ Hz), 7.63 (t, 1H, $J=8.4$ Hz), 7.39 (t, 1H, $J=8.4$ Hz), 5.25 (s br, 1H), 4.58 (sept, 1H, $J=6.6$ Hz), 3.80 (m, 2H), 3.73 (q, 2H, $J=7.0$ Hz), 3.23 (t br, 2H, $J=5.9$ Hz), 2.98 (t, 2H, $J=6.8$ Hz), 2.60 (t br, 2H, $J=6.8$ Hz), 1.86-1.74 (m, 4H), 1.63 (t, 2H, $J=6.6$ Hz), 1.39 (m, 4H), 1.21 (d, 6H, $J=6.6$ Hz), 1.20 (t, 3H, $J=7.0$ Hz).

$^{13}\text{C-NMR}$ (CDCl_3 , 300MHz, δ): 160.2, 154.6, 146.9, 148.1, 139.1, 131.7, 128.1, 124.9, 123.9, 53.3, 48.8, 46.8, 38.2, 31.3, 30.6, 29.0, 27.2, 26.7, 23.7, 22.0, 21.0, 12.6.

EI-MS: m/z $[\text{M}^+]^+$ 481.

Example 14: 2-Ethyl-4-isopropyl-5-[9-(1,2,3,4-tetrahydro-acridin-9-ylamino)-nonyl-iminio]-[1,2,4]thiadiazolidin-3-one.



Reagents: ethylisothiocyanate (569 μ l, 6.5 mmol), KMnO_4 (500mg, 3.16mmol), HCl (3.1ml, 3.4mmol), isopropylisocyanate (640 μ l, 6.5 mmol), triethylamine (140 μ l, 1.0 mmol) and 9-(9-aminononylamino)-1,2,3,4-tetrahydroacridine (173 mg, 0.5 mmol).


Purification: silica gel column chromatography using AcOEt/MeOH (15:1). Yellow syrup (36 mg, 14 %).

$^1\text{H-NMR}$ (CDCl_3 , 300MHz, δ): 7.94 (dd, 1H, $J=8.0$, 0.5 Hz), 7.90 (d, 1H, $J=8.8$ Hz), 7.53 (ddd, 1H, $J=8.2$, 7.1, 1.2 Hz), 7.32 (ddd, 1H, $J=8.2$, 7.1, 1.1 Hz), 4.59 (sept, 1H, $J=6.6$ Hz), 3.74 (q, 2H, $J=7.1\text{Hz}$), 3.48 (t, 2H, $J=7.1$ Hz), 3.01 (s br, 2H), 2.98 (t, 2H, $J=7.1$ Hz), 2.68 (s br, 2H), 1.91-1.88 (m, 4H), 1.66-1.59 (m, 4H), 1.29 (s br, 11H), 1.21 (d, 6H, $J=6.6$ Hz), 1.20 (t, 3H, $J=7.1$ Hz).

$^{13}\text{C-NMR}$ (CDCl_3 , 300MHz, δ): 158.5, 154.9, 148.5, 148.3, 139.5, 131.8, 128.7, 123.9, 123.1, 53.8, 49.8, 47.1, 38.5, 34.0, 32.0, 31.0, 29.7, 29.6, 27.6, 27.2, 25.0, 23.3, 22.9, 21.2, 12.9.

EI-MS: m/z $[\text{M}^+]^+$ 509.

Example 15: 4-isopropyl-3-oxo-5-[9-(1,2,3,4-tetrahydro-acridin-9-ylamino)-nonyl-iminio]-[1,2,4]thiadiazolidine-2-carboxylic acid ethyl ester.



Reagents: ethoxycarbonylmethylisothiocyanate (0.8 ml, 6.5 mmol), KMnO_4 (500mg, 3.16mmol), HCl (3.1ml, 3.4mmol), isopropylisocyanate (640 μl , 6.5 mmol), triethylamine (140 μl , 1.0 mmol) and 9-(9-aminononylamino)-1,2,3,4-tetrahydroacridine (173 mg, 0.5 mmol).

Purification: silica gel column chromatography using AcOEt/MeOH (15:1). Yellow syrup (10 mg, 0.1 %)


$^1\text{H-NMR}$ (CDCl_3 , 300MHz, δ): 7.98 (d, 2H, $J=7.8$ Hz), 7.57 (t, 1H, $J=7.6$ Hz), 7.35 (t, 1H, $J=7.6$ Hz), 4.59 (sept, 1H, $J=6.6$ Hz), 4.17 (q, 2H, $J=7.1$

Hz), 3.74 (q, 2H, $J=7.1$ Hz), 3.68-3.56 (m, 2H), 3.09 (s br, 2H), 2.98 (t, 2H, $J=6.8$ Hz), 2.65 (s br, 2H), 1.95-1.90 (m, 4H), 1.78-1.59 (m, 4H), 1.29-1.18 (m, 11H), 1.21 (d, 6H, $J=6.6$ Hz), 1.20 (t, 3H, $J=7.1$ Hz).

^{13}C -NMR (CDCl_3 , 300MHz, δ): 173.4, 151.6, 143.9, 148.3, 136.7, 131.8, 128.7, 123.6, 123.1, 77.2, 49.5, 42.3, 31.8, 30.7, 29.3, 26.9, 24.7, 23.0, 21.0, 14.1, 12.6.

EI-MS: m/z $[\text{M}+\text{H}]^+$ 554.

Example 16.- 4-Ethyl-2-propyl-5-[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl-imino]-[1,2,4]thiadiazolidin-3-one



Reagents: ethylisothiocyanate (0.57ml, 6.5 mmol), KMnO_4 (500mg, 3.16mmol), HCl (3.1ml, 3.4mmol), propylisocyanate (0.60ml, 6.5mmol), triethylamine (0.12ml, 1.26mmol) and 9-(7-aminoheptylamino)-1,2,3,4-tetrahydroacridine (200mg, 0.63mmol).


Purification: silica gel column chromatography using DCM/ MeOH (8:1). Yellow syrup (12 mg, 4%).

^1H -NMR(CDCl_3 , 400MHz, δppm): 8.35 (d, 1H, $J= 8.4$ Hz), 8.10 (d, 1H, $J= 8.4$ Hz), 7.63 (t, 1H, $J= 8.4$ Hz), 7.39 (t, 1H, $J= 8.4$ Hz), 4.95 (s br, 1H), 3.80 (c, 2H, $J= 7.0$ Hz), 3.66 (br, 2H), 3.40 (t, 2H, $J= 7.0$ Hz), 3.18 (br, 2H), 2.98 (t, 2H, $J= 7.0$ Hz), 2.60 (br, 2H), 1.86-1.74 (m, 4H), 1.65 (q, 2H, $J= 7.0$ Hz), 1.63 (br, 4H), 1.39 (m, 6H), 1.20 (t, 3H, $J= 7.0$ Hz), 0.95 (t, 3H, $J= 7.0$ Hz).

^{13}C -NMR (CDCl_3 , 100MHz, δ): 160.4, 154.6, 147.1, 148.1, 139.0, 131.7, 128.1, 124.9, 123.9, 53.3, 48.8, 46.8, 38.2, 31.3, 30.6, 29.0, 27.2, 26.7, 23.7, 22.0, 21.0, 12.8, 10.6.

EI-MS: m/z $[\text{M}^+]^+$ 481.

Example 17.- 4-Ethyl-2-isopropyl-5-[8-(1,2,3,4-tetrahydro-acridin-9-ylamino)-octylimino]-[1,2,4]thiadiazolidin-3-one



Reagents: ethylisothiocyanate (0.57ml, 6.5 mmol), KMnO_4 (500mg, 3.16mmol), HCl (3.1ml, 3.4mmol), isopropylisocyanate (0.60ml, 6.5 mmol), triethylamine (0.12ml, 1.26mmol) and 9-(8-aminooctylamino)-1,2,3,4-tetrahydroacridine (200mg, 0.61mmol).


Purification: silica gel column chromatography using DCM/MeOH (25:1). Yellow syrup (7 mg, 2.3%).

^1H -NMR (CDCl_3 , 400MHz, δ ppm): 8.36 (d, 1H, $J=8.4$ Hz), 8.09 (d, 1H, $J=8.4$ Hz), 7.63 (t, 1H, $J=8.4$ Hz), 7.39 (t, 1H, $J=8.4$ Hz), 4.58 (sept, 1H, $J=6.6$ Hz), 3.80 (m, 2H), 3.73 (c, 2H, $J=7.0$ Hz), 3.23 (t br, 2H, $J=5.9$ Hz), 3.00 (t, 2H, $J=6.8$ Hz), 2.60 (t br, 2H, $J=6.8$ Hz), 1.86-1.74 (m, 4H), 1.63 (m, 4H), 1.39 (m, 8H), 1.21 (d, 6H, $J=6.6$ Hz), 1.20 (t, 3H, $J=7.0$ Hz).

^{13}C -NMR (CDCl_3 , 100MHz, δ): 160.2, 154.6, 146.9, 148.1, 139.1, 131.7, 128.1, 124.9, 123.9, 53.3, 48.8, 46.8, 38.2, 31.3, 30.6, 29.0, 27.2, 26.7, 23.7, 22.0, 21.0, 12.6.

EI-MS: m/z $[\text{M}^+]^+$ 496.

Example 18.- 4-Ethyl-2-isopropyl-5-[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl-imino]-[1,2,4]thiadiazolidin-3-one



Reagents: ethylisothiocyanate (0.57ml, 6.5 mmol), KMnO_4 (500mg, 3.16mmol), HCl (3.1ml, 3.4mmol), isopropylisocyanate (0.60ml, 6.5 mmol), triethylamine (0.12ml, 1.26mmol) and 9-(6-aminohexylamino)-1,2,3,4-tetrahydroacridine (200mg, 0.66mmol).


Purification: silica gel column chromatography using DCM/ MeOH (25:1). Yellow syrup (5 mg, 1.6 %).

$^1\text{H-NMR}$ (CDCl_3 , 100MHz, δ ppm): 8.36 (d, 1H, $J= 8.4$ Hz), 8.09 (d, 1H, $J= 8.4$ Hz), 7.63 (t, 1H, $J= 8.4$ Hz), 7.39 (t, 1H, $J= 8.4$ Hz), 5.25 (s br, 1H), 4.58 (sept, 1H, $J= 6.6$ Hz), 3.80 (m, 2H), 3.73 (c, 2H, $J= 7.0$ Hz), 3.23 (t br, 2H, $J= 5.9$ Hz), 2.98 (t, 2H, $J= 6.8$ Hz), 2.60 (t br, 2H, $J= 6.8$ Hz), 1.86-1.74 (m, 4H), 1.63 (t, 4H, $J= 6.6$ Hz), 1.39 (m, 4H), 1.21 (d, 6H, $J=6.6$ Hz), 1.20 (t, 3H, $J= 7.0$ Hz).

$^{13}\text{C-NMR}$ (CDCl_3 , 400MHz, δ): 1610.5, 154.4, 146.9, 148.1, 139.1, 132.0, 128.1, 124.9, 123.9, 53.3, 48.8, 46.8, 37.5, 31.3, 30.6, 29.0, 27.2, 26.7, 23.7, 22.0, 21.0, 13.0.

EI-MS: m/z $[\text{M}^+]^+$ 468.

Example 19.- N-[2-(6-Chloro-1,2,3,4,4a,9a-hexahydro-acridin-9-ylamino)-ethyl]-N'-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-N-methylethane-1,2-diamine



To a solution of 6,9-Dichloro-1,2,3,4-tetrahydro-acridine (1 gr, 3.9mmol) in 1-pentanol (20 ml) was added *N*¹-(3-Amino-propyl)-*N*¹-methyl-propane-1,3-diamine (1.7gr, 11.8 mmol and the mixture was refluxed for 12 hours. After this time the 1-pentanol was evaporated under reduced pressure, and then the resulting residue was dissolved in dichloromethane and was washed with 10% NaOH. The combined organic extracts were dried with Na₂SO₄ anhydrous. The solvent was evaporated under reduced pressure and the residue purified by silica gel column chromatography using DCM/ MeOH/ NH₃ (10:1:0.5%) (20:1:0.5%). Yellow syrup, yield: 51 mg (25%).


¹H-NMR (CDCl₃, 400MHz, δ ppm): 7.93 (d, 2H, *J*=1.9 Hz), 7.90 (d, 2H, *J*=8.9 Hz), 7.16 (dd, 2H, *J*=8.9 Hz, *J*=1.9 Hz), 3.71 (m, 4H), 3.02 (m, 4H), 2.61 (m, 8H), 2.05 (s, 3H), 1.92-1.85 (m, 12H).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 159.5, 150.8, 148.3, 133.9, 127.7, 124.7, 124.2, 118.0, 115.8, 56.6, 50.2, 43.1, 27.2.

ESI-MS[M+H⁺]⁺576.


General method for the synthesis of THA-acridine derivatives (Scheme 6, Examples 20-24)

To a solution of 9-alkylaminotetrahydroacridines in 1-pentanol was added the 9-aminotetrahydroacridines and the mixture was refluxed for 4 hours. After this time the 1-pentanol was evaporated under reduced pressure, and then the resulting residue was dissolved in dichloromethane and was washed with 10% NaOH. The combined organic extracts were dried with Na₂SO₄ anhydrous. The solvent was evaporated under reduced pressure and the residue purified by silica gel column chromatography using as eluent mixtures of solvents in the proportions indicated for each case.



SCHEME 6

Example 20.- N-Acridin-9-yl-N'-(1,2,3,4-tetrahydro-acridin-9-yl)-nonane-1,9-diamine



Reagents: N1-(1,2,3,4-Tetrahydro-acridin-9-yl)-nonane-1,9-diamine (143 mg, 0.46 mmol), 1-pentanol (10 ml), 9-Chloro-acridine (99 mg, 0.46 mmol).


Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (10:1: 0.5%). Yellow syrup, yield: 128 mg (57%).

^1H -NMR (CDCl_3 , 400MHz, δ ppm): 8.10 (d, 2H, $J=8.9$ Hz), 8.06 (d, 2H, $J=8.6$ Hz), 7.94 (d, 1H, $J=7.4$ Hz), 7.90 (d, 1H, $J=7.4$ Hz), 7.64 (t, 2H, $J=7.0$ Hz), 7.55 (t, 1H, $J=7.0$ Hz), 7.35 (m, 3H), 3.83 (t, 2H, $J=7.0$ Hz), 3.47 (t, 2H, $J=7.0$ Hz), 3.07 (m, 2H), 2.69 (m, 2H), 1.92 (m, 4H), 1.79 (q, 2H, $J=7.0$ Hz), 1.64 (q, 2H, $J=7.0$ Hz), 1.38-1.30(m, 10H).

^{13}C -NMR (CDCl_3 , 100MHz, δ ppm): 158.0, 150.5, 129.8, 128.4, 128.0, 123.3, 122.7, 116.1, 115.6, 50.6, 49.3, 34.0, 31.7, 31.6, 29.3, 29.1, 26.8, 24.8, 23.0, 22.8 .

ESI-MS $[\text{M}+\text{H}^+]+491$.

Example 21.- *N*-Acridin-9-yl-*N'*-[2-(1,2,3,4,4a,9a-hexahydro-acridin-9-ylamino)-ethyl]-*N'*-methyl-ethane-1,2-diamine



Reagents: *N*-(2-Amino-ethyl)-*N*-methyl-*N'*-(1,2,3,4-tetrahydro-acridin-9-yl)-ethane-1,2-diamine (143 mg, 0.44 mmol), 1-pentanol (10 ml), 9-Chloro-acridine (115.5 mg, 0.53mmol).

Purification: silica gel column chromatography using DCM/ MeOH/ NH_3 (20:1:0.5%). Yellow syrup, yield: 51 mg (23%).


^1H -NMR (CDCl_3 , 400MHz, δ ppm): 8.09 (d, 2H, $J=8.6$ Hz), 7.98 (d, 2H, $J=8.6$ Hz), 7.80 (d, 2H, $J=8.6$ Hz), 7.44 (t, 2H, $J=7.4$ Hz), 7.29 (t, 2H, $J=7.4$ Hz), 7.09 (m, 3H), 4.07 (m, 2H), 3.66 (m, 2H), 2.93 (m, 2H), 2.67 (m, 2H), 2.62 (m, 2H), 2.48 (m, 2H) 2.31 (s, 3H), 2.04 (m, 2H), 1.91 (m, 2H), 1.66 (m, 4H).

^{13}C -NMR (CDCl_3 , 100MHz, δ ppm):155.5, 141.8, 140.9, 132.9, 132.8, 130.0, 126.3, 124.5, 124.1, 124.0, 123.4, 122.8, 121.5, 120.9, 120.7,

117.7, 117.5, 113.2, 56.5, 56.3, 56.0, 50.0, 48.5, 47.9, 42.6, 42.4, 33.4, 28.3, 26.1, 24.6, 22.6.

ESI-MS[M+H]⁺504.

Example 22.- *N*-[2-(Acridin-9-ylamino)-ethyl]-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-*N*-methyl-ethane-1,2-diamine



Reagents: *N*'-[2-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-ethyl]-*N*-methyl-ethane-1,2-diamine (350 mg, 0.96 mmol), 1-pentanol (13 ml), 9-Chloro-acridine (207 mg, 0.96 mmol).

Purification: silica gel column chromatography using DCM/ MeOH/ NH₃ (10:1:0.5%). Yellow syrup, yield: 132 mg (25%).


¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.07 (m, 4H), 7.83 (d, 2H, *J*=2.3 Hz), 7.76 (d, 2H, *J*=8.6 Hz), 7.61 (t, 2H, *J*=7.4 Hz), 7.24 (t, 2H, *J*=7.4 Hz), 7.12 (dd, 1H, *J*=7.4 Hz, *J*=2.3 Hz), 4.01 (t, 2H, *J*=6.2 Hz), 3.51 (m, 2H), 2.98 (t, 2H, *J*=6.2 Hz), 2.67 (t, 2H, *J*=6.2 Hz), 2.58 (m, 2H), 2.40 (s, 3H), 1.92 (m, 4H), 1.80 (m, 4H).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 158.0, 150.5, 129.8, 128.4, 128.0, 123.3, 122.7, 116.1, 115.6, 50.6, 49.3, 34.0, 31.7, 31.6, 29.3, 29.1, 26.8, 24.8, 23.0, 22.8.

ESI-MS[M+H]⁺542.

Example 23.- *N*-Acridin-9-yl-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-heptane-1,7-diamine

42




Reagents: *N'*-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-yl)-heptane-1,7-diamine (385 mg, 1.11 mmol), 1-pentanol 10 ml) and 9-Chloro-acridine (236 mg, 1.11 mmol).

Purification: silica gel column chromatography using. AcOEt/ MeOH/ NH₃ from (15:1:0) to (9:1:0.5). Yellow solid. Yield: 162 mg (30%)

¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.1-8.04 (m, 4H), 7.86 (d, 1H, *J*=8.8 Hz), 7.4 (d, 1H, *J*=2.4 Hz), 7.61 (t, 2H, *J*=7.4 Hz), 7.36 (t, 2H, *J*=7.4 Hz), 7.22 (dd, 1H, *J*=7.4 Hz, *J*=2.4 Hz), 3.90 (brs, 1H), 3.80 (t, 2H, *J*=7.4), 3.42-3.45 (m, 2H), 3.02 (m, 2H), 2.63 (m, 2H), 1.90-1.89 (m, 4H), 1.77-1.74 (m, 2H), 1.60-1.64 (m, 2H), 1.44-1.30 (m, 6H). ¹³C-NMR (CDCl₃, 100MHz, ppm): 159.7, 151.5, 150.7, 148.35, 134.0, 129.9, 127.8, 124.6, 124.3, 123.2, 122.7, 118.6, 116.8, 116.0, 60.6, 51.1, 49.8, 34.4, 32.0, 29.3, 27.1, 24.9, 23.3, 23.0, 21.4.

ESI-MS[M+H]⁺523.

Example 24.- *N*-Acridin-9-yl-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-octane-1,8-diamine



Reagents: *N'*-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-yl)-octane-1,8-diamine (165 mg, 0.46 mmol), 1-pentanol (5 ml), and 9-Chloro-acridine (99.8 mg, 0.46 mmol).

Purification: silica gel column chromatography using. AcOEt/ MeOH/ NH₃ from (15:1:0%) to (9:1:0.5%). Yellow solid. Yield: 19 mg (8%).

¹H-NMR (CDCl₃, 400MHz, δ ppm): 8.02-8.12 (m, 4H), 7.87 (d, 1H, J=8.4 Hz), 7.88 (d, 1H, J=1.6 Hz), 7.64 (t, 2H, J=7.8 Hz), 7.34 (t, 2H, J=7.6 Hz), 7.22 (m, 1H), 3.90 (brs, 1H), 3.80 (t, 2H, J=7.4), 3.49 (m, 2H), 3.02 (m, 2H), 2.65 (m, 2H), 1.90 (m, 4H), 1.78 (m, 2H), 1.60-1.64 (m, 2H), 1.20-1.40 (m, 8H).

¹³C-NMR (CDCl₃, 100MHz, δ ppm): 159.7, 150.8, 148.3, 134.0, 130.0, 127.9, 124.7, 124.3, 123.2, 122.8, 118.7, 118.6, 116.0, 61.0, 51.1, 49.0, 34.5, 32.1, 29.5, 27.1, 25.0, 23.3, 23.1, 21.4.






ESI-MS[M+H]⁺+535.

BIOLOGICAL EVALUATION

ACHE INHIBITION (FROM HUMAN ERYTHROCYTES)

The method of Ellman *et al.* (Ellman, G.L.; Courtney, K.D.; Andres, B.; Featherstone, R.M. *Biochem. Pharmacol.* 1961, 7, 88-95) was followed. The assay solution consisted of 0.1 M phosphate buffer pH 8, 200 μ M 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, Ellan's reagent), 0.02 unit/ml AChE (Sigma Chemical Co. from human erythrocytes), and 400 μ M acetylthiocholine iodide as the substrate of the enzymatic reaction. The compounds tested were added to the assay solution and pre incubated with the enzyme for 10 min at 30°C. After that period, the substrate was added. The absorbance changes at 412 nm were recorded for 5 min with a Perkin-Elmer 550 SE UV/VIS spectrometer, the reaction rates were compared, and the percent inhibition due to the presence of test compounds was calculated. The IC₅₀ is defined as the concentration of each compound that reduces a 50% the enzymatic activity with respect to that without inhibitors.

Table 1: Human Erythrocytes AChE inhibition

Compound number	Structure	IC ₅₀ (nM)
1		25
2		100
13		250
14		120
15		120

AChE INHIBITION (FROM BOVINE ERYTHROCYTES)

AChE inhibitory activity was evaluated at 25°C by the colorimetric method reported by Ellman (Ellman, G.L.; Courtney, K.D.; Andres, B.; Featherstone, R.M. *Biochem. Pharmacol.* 1961, 7, 88-95). The assay solution consisted on 0.02 unit/ml AChE from bovine erythrocytes, 0.1 M sodium phosphate buffer pH 8, 0.3 mM 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB, Ellman-s reagent), and 0.5 mM acetylthiocholine iodide as

the substrate of the enzymatic reaction. Enzyme activity was determined by measuring the absorbance at 405 nm during 10 minutes with a Fluostar optima plate reader (BMG). The tested compounds were preincubated with the enzyme for 10 minutes at 30°C. In this conditions, compound 16 showed an IC₅₀ value of 2.03 E-07 M.

NEURONAL AChE ACTIVITY

Acetylcholinesterase (AChE) enzyme preparations were obtained from SH-SY5Y, SK-N-SH and N2A cells.

CELL CULTURE: The human neuroblastoma cell line SH-SY5Y was cultured in minimum essential medium, Han's F12 medium, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, and grown in a 5% CO₂ humidified incubator at 37°C. The human neuroblastoma cell line SK-N-SH was cultured in RPMI 1640 medium, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, and grown in a 5% CO₂ humidified incubator at 37°C. The rat neuroblastoma cell line N2A was cultured in DULBECCO'S MOD EAGLE medium, supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin, and grown in a 5% CO₂ humidified incubator at 37°C. The cells were plated at 250·10³ cells for each reaction, at least, 48 hours before the AChE activity measure. Cells were washed and harvested in 0.1 M sodium phosphate buffer pH 8, at 4°C.

INHIBITION OF AChE: AChE inhibitory activity was evaluated at 25°C by the colorimetric method reported by Ellman (Ellman, G.L.; Courtney, K.D.; Andres, B.; Featherstone, R.M. *Biochem. Pharmacol.* 1961, 7, 88-95). The assay solution consisted of AChE from neuronal cells, 0.1 M phosphate buffer pH 8, 0.3 mM 5,5'-dithiobis (2-nitrobenzoic acid)

(DTNB, Ellman-s reagent), and 0.5 mM acetylthiocholine iodide as the substrate of the enzymatic reaction. Enzyme activity was determined by measuring the absorbance at 405 nm during 10 minutes with a Fluostar optima plate reader (BMG). The tested compounds were preincubated with the enzyme for 10 minutes at 30°C. The reaction rate was calculated with, at least, triplicate measurements, and the percent inhibition due to the presence of test compound was calculated relative to the compound-free control. The compound concentration producing 50% of AChE inhibition (IC₅₀) was determined.

		IC ₅₀ (M)		
		N2A (rat neuroblastoma)	SK-N-SY (human neuroblastoma)	SH-SY5Y (human neuroblastoma)
AChE inhibitors	1	2,09E-07	1,09E-07	4,35E-06
	13	4,24E-07	4,13E-07	3,00E-07
	14	4,46E-07	4,41E-07	3,33E-07
	15	5,61E-07	7,78E-07	3,91E-07
	Tacrine	3,95E-07	3,03E-07	3,91E-07

INHIBITION OF β -AMYLOID AGGREGATION:

The generation of AChE-A β complexes were carried out as described previously [39,40]. Stock solutions of A β ₁₋₄₀ at 3.5 mM were prepared in DMSO. The amount of peptide used in the assays was 0.1 mM. Human recombinant AChE (Sigma-Aldrich) was used at a molar

ratio A β -AChE 200:1. For the aggregation studies the peptide was mixed with the appropriate amount of AChE in PBS pH 7.4 and stirred for 48 hours in a microtiter plate at room temperature. The fibrils obtained were characterized by Congo Red (CR) binding.

For the inhibition of β -amyloid aggregation, the compounds tested were used at the IC₅₀ defined in the previous paragraph of the biological evaluation. Propidium iodide 50 μ M for comparison.

To quantify the amount of fibrils aggregated, the binding to CR was done as described by Klunk (Klunk, WE.; Pettegrew, JW.; Abraham, DJ. *J. Histochem. Cytochem.*, 1989, 8, 1293-1297). Briefly, 5.5 μ l aliquot of the aggregation mixture were added to 132 μ l of a solution of 25 M CR (100mM phosphate buffer pH 7.4, 150mM NaCl) and incubated for 30 minutes at room temperature. Absorbance was measured at 480 and 540nm. The CR binding was estimated by $CR (M) = (A_{540}/25295) - (A_{480}/46306)$.

In the conditions above described, the indanone-tacrine derivative 1 showed a 18.7% reduction of the amyloid-AChE complex aggregation, while the thiadiazolidinone-tacrine derivative 15 decrease the β -amyloid-AChE complex aggregation by 27.8%. The peripheral inhibitor propidium reduces the aggregation of the β -amyloid-AChE complex by 18.1 %. This compound was used as standard of reference.

ACETYLCHOLINESTERASE (AChE) INHIBITION (FROM BOVINE ERYTHROCYTES)

AChE inhibitory activity was evaluated at 30°C by the colorimetric method reported by Ellman [Ellman, G.L.; Courtney, K.D.; Andres, B.; Featherstone, R.M. *Biochem. Pharmacol.* 1961, 7, 88-95]. The assay solution consisted of 0.1 M phosphate buffer pH 8, 0.3 mM 5,5'-

dithiobis (2-nitrobenzoic acid) (DTNB, Ellman's reagent), 0.02 units AChE (Sigma Chemical Co. from bovine erythrocytes), and 0.5 mM acetylthiocholine iodide as the substrate of the enzymatic reaction. The compounds tested were added to the assay solution and preincubated with the enzyme for 5 min at 30°C. After that period, the substrate was added. The absorbance changes at 405 nm were recorded for 5 min with a microplate reader Digiscan 340T, the reaction rates were compared, and the percent inhibition due to the presence of test compounds was calculated. The reaction rate was calculated with, at least, triplicate measurements, and the percent inhibition due to the presence of test compound was calculated relative to the compound-free control. The compound concentration producing 50% of AChE inhibition (IC_{50}) was determined. The results are shown in table 2.

BUTYRYLCHOLINESTERASE (BuChE) INHIBITION (FROM HUMAN SERUM)

BuChE inhibitory activity was evaluated at 30°C by the colorimetric method reported by Ellman [Ellman, G.L.; Courtney, K.D.; Andres, B.; Featherstone, R.M. *Biochem. Pharmacol.* 1961, 7, 88-95]. The assay solution consisted of 0.01 units BuChE from human serum, 0.1 M sodium phosphate buffer pH 8, 0.3 mM 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB, Ellman's reagent), and 0.5 mM butyrylthiocholine iodide as the substrate of the enzymatic reaction. Enzyme activity was determined by measuring the absorbance at 405 nm during 5 minutes with a microplate reader Digiscan 340T. The tested compounds were preincubated with the enzyme for 10 minutes at 30°C. The reaction rate was calculated with, at least, triplicate measurements. The IC_{50} is defined as the concentration of each compound that reduces a 50% the enzymatic activity with respect to that without inhibitors. The results are shown in table 2.

TOXICITY MEASUREMENT

The cytotoxicity effect of the molecules was tested in the human neuroblastoma cell line SH-SY5Y. These cells were cultured in 96-well plates in minimum essential medium, Han's F12 medium, supplemented with 10% fetal bovine serum, 1% glutamine and 1% penicillin/streptomycin, and grown in a 5% CO₂ humidified incubator at 37°C.

The cells were plated at 10⁴ cells for each well, at least, 48 hours before the toxicity measure. Cells were exposed for 24 hours to the compounds at different concentrations (from 10⁻⁵ to 10⁻⁹), quantitative assessment of cell death was made by measurement of the intracellular enzyme lactate dehydrogenase (LDH) (citotoxicity detection kit, Roche). The quantity of LDH was evaluated in a microplate reader Anthos 2010, at 492 and 620 nm. Controls were taken as 100% viability. The results are shown in table 2.

PROPIDIUM COMPETITION

Propidium exhibits an increase in fluorescence on binding to AchE peripheral site, making it a useful probe for competitive ligand binding to the enzyme.

Fluorescence was measured in a Fluostar optima plate reader (BMG). Measurements were carried out in 100 µl solution volume, in 96-well plates. The buffer used was 1 mM Tris/HCl, pH 8.0. 10 M AchE was incubated, at least 6 hours, with the molecules at different concentrations. 20 µM propidium iodide was added 10 min before fluorescence measurement. The excitation wavelength was 485 nm, and that of emission, 620 nm. The results are shown in table 2.

EFFECTS ON CALCIUM CHANNELS

We have studied if these compounds are able to block calcium channels. Calcium entry in SH-SY5Y cells was stimulated with 60 mM K⁺ in 96-well plates. Cells were plated at 5·10⁴ for each well, at least, 48 hours before the experiment. For measurement of intracellular calcium, SH-SY5Y were washed with Krebs/HEPES buffer, pH 7.4. and cells were loaded with the calcium indicator dye Fluo-4 (Molecular Probes) for 40 min at 37°C followed by 15 min post incubation at room temperature. Intracellular calcium was measured fluorometrically in a Fluostar optima plate reader (BMG), with excitation wavelengths set at 485 nm and emission at 520 nm. The tested compounds were preincubated with the cells for 10 minutes before the depolarization with K⁺. The results are shown in table 2.

ANTIOXIDANT ACTIVITY








In order to evaluate if these compounds have antioxidant properties cells SH-SY5Y were exposed 24 hours to 100 M H₂O₂, previously these cells were pretreated for 1 hour with the molecules at different concentrations (from 10⁻⁵ to 10⁻⁹). The antioxidant activity is evaluated measuring cellular viability, using the LDH assay. Cells SH-SY5Y were cultured in 96-well plates as toxicity experiments. The results are shown in table 2.







EFFECTS ON β -AMILOID TOXICITY







We have tested if some of these molecules interfere with - amyloid peptide toxicity. Cells SH-SY5Y were cultured in 96-well plates

as toxicity experiments. Cells were pretreated for 1 hour with the compounds at different concentrations (from 10^{-5} to 10^{-9}), immediately neuronal death is induced adding synthetic peptide β -amyloid, fragment 25-35 (A₂₅₋₃₅) at 200 μ M. 24 hours later cell viability was assessed with the LDH assay; results are reported relative to untreated wells. The results are shown in table 2.

TABLE 2

Comp no.	structure	IC ₅₀ AchE (nM)	IC ₅₀ BuChE (nM)	Toxicity (μM)
3		500	100	10
4		3000	10	>100
5		90	30	5
6		900	8	>100
7		1500	700	>100
8		1000	1000	100
9		2	90	>100

10		20	650	>100
11		3	75	>100
12		10	200	>100
16		450	20	50
17		200	10	>100
18		2250	1000	>10


19		0.1	1.5	10
20		20	10	10
21		4	70	>100
22		0.1	60	10
23		0.4	20	0.5
24		1	35	5

Comp no	Toxicity (μ M)	Propidium competition (μ M)	Calcium channel blockade (μ M)	Antioxidant activity (μ M)	inhibition of $A\beta_{(25-35)}$ toxicity (μ M)
3	10	>100	NO	NO	
4	>100	10	NO	NO	
5	5	>100	NO	NO	
6	>100	10	NO	NO	
7	>100	100	10	NO	1
8	100	>100	NO	NO	
9	>100	1	NO	NO	
10	>100	10	NO	NO	
11	>100	10	NO	NO	

12	>100	100	NO	NO	
16	50	>100	NO	NO	
17	>100	0.1	NO	NO	
18	>10	>100	NO	NO	
19	10	10	NO	NO	
20	10	100	NO	NO	
21	>100	1000	NO	10	
22	10	10	NO	NO	
23	0.5	1	NO	NO	1
24	5	10	NO	NO	

CLAIMS


1. A compound represented by the general formula (I)



Formula I

wherein:

X is one of the following radicals:



L is independently selected from $-C(R)(R'')$ -, $-CO-$, $-O-$ or $-NR'-$

n is zero, one, two, three, four, five, six, seven, eight, nine or ten

R and R'' are independently selected from hydrogen, alkyl, aryl, heteroaryl, halo, haloalkyl, alkoxy, hydroxyl, nitro and alkylthio

D is independently selected from $-C(R_9)-$, $=C-$, or $-N-$

A_1 , A_2 , A_3 , A_4 , A_5 , A_7 , A_8 , B_1 , B_2 , B_3 , B_4 , B_5 , B_6 , B_7 , B_8 , C and G are independently selected from $-CO-$, $-C(R_{10})(R_{11})-$, $=C(R_{10})-$, $-N(R_{12})-$, $=N-$, $-O-$, $-S(O)_t-$

R_1 , R_2 , R_3 , R_4 , R_9 , R_{10} and R_{11} are independently selected from hydrogen, alkyl, alkoxy, hydroxyl, alkylthio, cycloalkyl, haloalkyl, halo, aryl, $-(Z)_n-$, aryl, heteroaryl, $-O(R_7)$, $-C(O)R_7$, $-C(O)OR_7$, $-S(O)_t$, cyano, nitro and mercapto, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio


R_5 , R_6 , and R_{12} are independently selected from hydrogen, alkyl, alkoxy, hydroxyl, cycloalkyl, haloalkyl, aryl, heteroaryl, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

Z is independently selected from $-C(R_7)(R_8)-$, $-C(O)-$, $-O-$, $-C(=NR_7)-$, $-S(O)_t$, $N(R_7)-$

R_7 and R_8 are independently selected from hydrogen, alkyl, alkoxy, alkylthio, cycloalkyl, haloalkyl, halo, aryl, heteroaryl, cyano, nitro, mercapto, aryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio; and heteroaryl substituted by alkyl, alkoxy, hydroxy, halo, haloalkyl, nitro or alkylthio

t is zero, one or two;


with the proviso that when X is:



then

- (a) each of the groups A₁ to A₈ and B₁ to B₈ is not =C(R₁₀)-, and
- (b) each of the groups A₁ to A₄ and B₁ to B₄ is not =C(R₁₀)- when each of the groups A₅ to A₈ and B₅ to B₈ is -C(R₁₀)(R₁₁)-.

2. A compound according to claim 1 wherein X is a group:



where D, E, G, R₁, R₂, R₃ and R₄ are as defined.

- 3. A compound according to claim 2, wherein X is selected from phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl), indol-2-yl, 1-indanon-2-yl, benzimidazol-2-yl, indadion-2-yl, indazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, or benzotriazol-2-yl
- 4. A compound according to claim 2 wherein X is phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl) and the cyclic part of formula I

represents 9-acridinyl, 1,2,3,4-tetrahydro-acridin-9-yl or 6-chloro, 1,2,3,4-tetrahydro-acridin-9-yl.

5. A compound according to claim 2 which is:


- 2-[6-(acridin-9-ylamino)-hexyl]-isoindole-1,3-dione (6),
- 2-[7-(acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (7),
- 2-[8-(acridin-9-ylamino)-octyl]-isoindole-1,3-dione (8),
- 2-[9-(acridin-9-ylamino)-nonyl]-isoindole-1,3-dione (9),
- N-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (10),
- N-(3-{[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino}-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (11),
- N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (12),
- 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione (3),
- 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (4), or
- 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione (5)

6. A compound according to claim 2 wherein X is 1-indanon-2-yl and the cyclic part of formula I represents 1,2,3,4-tetrahydro-acridin-9-yl

7. A compound according to claim 6 which is:

- 5,6-Dimethoxy-2-{{7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl}-indan-1-one (1) or
 - 5,6-Dimethoxy-2-{{6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl}-indan-1-one (2)
8. A compound according to claim 1 wherein X is selected from the group formed by: 9-acridinyl, 6-chloro,1,2,3,4-tetrahydro-acridin-9-yl and 1,2,3,4-tetrahydro-acridin-9-yl.
9. A compound according to claim 8 wherein the cyclic part of formula I represents 9-acridinyl, 6-chloro,1,2,3,4-tetrahydro-acridin-9-yl and 1,2,3,4-tetrahydro-acridin-9-yl.
10. A compound according to claim 9 which is:
- N-[2-(6-Chloro-1,2,3,4,4a,9a-hexahydro-acridin-9-ylamino)-ethyl]-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-*N*-methyl-ethane-1,2-diamine (19),
 - N-Acridin-9-yl-*N'*-(1,2,3,4-tetrahydro-acridin-9-yl)-nonane-1,9-diamine (20)
 - *N*-Acridin-9-yl-*N'*-[2-(1,2,3,4,4a,9a-hexahydro-acridin-9-ylamino)-ethyl]-*N'*-methyl-ethane-1,2-diamine (21) ,
 - *N*-[2-(Acridin-9-ylamino)-ethyl]-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-*N*-methyl-ethane-1,2-diamine (22),
 - *N*-Acridin-9-yl-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-heptane-1,7-diamine (23), and
 - *N*-Acridin-9-yl-*N'*-(6-chloro-1,2,3,4-tetrahydro-acridin-9-yl)-octane-1,8-diamine (24).


11. A compound according to claim 1 wherein X is represented by a radical of the formula:



and in which the cyclic part of formula I represents 9-acridinyl, 6-chloro,1,2,3,4-tetrahydro-acridin-9-yl or 1,2,3,4-tetrahydro-aceridin-9-yl.

12. A compound according to claim 11 which is:
- 2-Ethyl-4-isopropyl-5-[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl-iminio]-[1,2,4]thiadiazolidin-3-one (13),
 - 2-Ethyl-4-isopropyl-5-[9-(1,2,3,4-tetrahydro-acridin-9-ylamino)-nonyl-iminio]-[1,2,4]thiadiazolidin-3-one (14),
 - 4-isopropyl-3-oxo-5-[9-(1,2,3,4-tetrahydro-acridin-9-ylamino)-nonyl-iminio]-[1,2,4]thiadiazolidine-2-carboxylic acid ethyl ester (15),
 - 4-Ethyl-2-propyl-5-[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl-imino]-[1,2,4]thiadiazolidin-3-one (16),
 - 4-Ethyl-2-isopropyl-5-[8-(1,2,3,4-tetrahydro-acridin-9-ylamino)-octylimino]-[1,2,4]thiadiazolidin-3-one (17), or
 - 4-Ethyl-2-isopropyl-5-[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl-imino]-[1,2,4]thiadiazolidin-3-one (18).
13. A pharmaceutical formulation containing as active ingredient a compound as defined in any of claims 1 to 12.

14. Compound according to claims 1 to 12 for use as a medicament
15. Compound according to claims 1 to 12 for use in treating cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.
16. Use of a compound according to claims 1 to 12 for preparing a medicament.
17. Use of a compound according to claims 1 to 12 for the manufacture of a medicament for treating cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.
18. A method of treating a cognitive disorder, which comprises administering an effective amount of a compound as defined in claim 1.



Figure

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032929 A3

(51) International Patent Classification⁷: **A61K 31/473**,
C07D 219/12, 401/12, 417/12

(21) International Application Number:
PCT/GB2003/004314

(22) International Filing Date: 7 October 2003 (07.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0223494.6 9 October 2002 (09.10.2002) GB

(71) Applicant (for all designated States except US): **NEUROPHARMA, S.A.** [ES/ES]; Jose Abascal 2, E-28003 Madrid (ES).

(71) Applicant (for SD only): **RUFFLES, Graham, Keith** [GB/GB]; Wellington House, East Road, Cambridge CB1 1BH (GB).

(72) Inventors; and



(75) Inventors/Applicants (for US only): **MARTINEZ GIL, Ana** [ES/ES]; Calle Santa Teresa 12, 2 Izquierda, E-28004

Madrid (ES). **DORRONSORO DIAZ, Isabel** [ES/ES]; C/Valliciego, 3 Portal 3 5° A, E-28005 Madrid (ES). **RUBIO ARRIETA, Laura** [ES/ES]; C/Esalona 57 7°3, E-28024 Madrid (ES). **ALONSO GORDILLO, Diana** [ES/ES]; C/Ramón y Cajal, 2 Portal 8 3°C, E- Madrid (ES). **FUERTE HUERTA, Ana** [ES/ES]; C/Alenza 9, 5° derecha, E-28003 Madrid (ES). **MORALES-ALCELAY, Susana** [ES/ES]; Avda. Infante Don Luis, n°14, P3, 1°A, Boadilla del Monte, E-28660 Madrid (ES). **DEL MONTE MILLÁN, Maria** [ES/ES]; C/Ramón Gómez de la Serna, n°51, 2A, E-28035 Madrid (ES). **GARCIA PALOMERO, Esther** [ES/ES]; C/Santa Teresa, n°7, 3 Izda, Leganés, E-28911 Madrid (ES). **USAN EGEA, Paola** [ES/ES]; C/Doctor Varela 31, 3°A Alpedrete, E-28430 Madrid (ES). **DE AUSTRIA, Celia** [ES/ES]; Avda. Moratalaz 29, Bj-C, E-28030 Madrid (ES). **MEDINA PADILLA, Miguel** [ES/ES]; C/Antonio López Aguado, 9; 9° G, E-28029 Madrid (ES).

(74) Agent: **RUFFLES, Graham, Keith**; Marks & Clerk, 66/68 Hills Road, Cambridge, Cambridgeshire CB2 1LA (GB).

[Continued on next page]

(54) Title: DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE



(57) Abstract: A family of compounds of formula (I) wherein: X is one of the following radicals: (a), (b), (c) which behaves as dual site acetylcholinesterase inhibitors and which are especially useful for the treatment of cognitive disorders as senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimer's disease, Parkinson disease, ALS, or prion diseases, as Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinker disease.

WO 2004/032929 A3



(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) **Date of publication of the international search report:**

1 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PI GB 03/04314

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/473 C07D219/12 C07D401/12 C07D417/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HU, MING-KUAN ET AL: "Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, 26 April 2002 (2002-04-26), pages 2277-2282, XP002267304 the whole document	1-18
X	CASTRO ET AL: "Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimer's Disease" MINI REVIEWS IN MEDICINAL CHEMISTRY, vol. 1, 2001, pages 267-272, XP001157056 cited in the application the whole document	1-18

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 January 2004

Date of mailing of the international search report

26 04 04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cortés, J

INTERNATIONAL SEARCH REPORT

International Application No

P/ GB 03/04314

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/17529 A (UNITECH PHARMACEUTICALS INC (US)) 15 March 2001 (2001-03-15) cited in the application the whole document	1-18
X	----- DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOUSSEF, KHAIRIA M.: "Synthesis and pharmacological screening of certain substituted tetrahydropyrido[4,3-b]quinolines and pyrazolo[4,3-c]quinolines" XP002267190 retrieved from STN Database accession no. 136:118414 abstract & AL-AZHAR BULLETIN OF SCIENCE (1999), 10(1), 99-112,	1,2
X	----- DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOUSSEF, KHAIRIA M. ET AL: "Synthesis and pharmacological screening of certain substituted tetrahydropyrido [4,3-b] quinolines and pyrazolo [4,3-c] quinolines" XP002267193 retrieved from STN Database accession no. 125:1080 abstract & BULLETIN OF THE FACULTY OF PHARMACY (CAIRO UNIVERSITY) (1995), 33(1), 33-9, -----	1,2

INTERNATIONAL SEARCH REPORT

national application No.
PCT/GB 03/04314

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 18 is directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 (partly), 2-7, 13-18 (partly)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 18 is directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.

Continuation of Box I.1

Claims Nos.: -

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (partly), 2-7, 13-18 (partly)

compounds wherein X is the first radical (i.e. phthalimide derivatives and related radicals)

2. claims: 1 (partly), 8-10, 13-18 (partly)

compounds wherein X is the second radical (i.e. 9-acridinyl derivatives and related radicals)

3. claims: 1 (partly), 11, 12, 13-18 (partly)

compounds wherein X is the third radical (i.e. 5-imino-(1,2,4)-thiazolidin-3-one derivatives and related radicals)

International Application No

Patent document
cited in search reportPublication
date

Patent family member(s)

Publication date

WO 0117529	A	15-03-2001	US	6194403	B1	27-02-2001
			AU	6932000	A	10-04-2001
			CA	2382706	A1	15-03-2001
			CN	1288893	A	28-03-2001
			WO	0117529	A1	15-03-2001